Bayer: EU approves precision oncology drug Vitrakvi
(CercleFinance.com) - Bayer said that the European Commission has granted marketing authorisation for its precision oncology drug Vitrakvi to treat solid tumors that have a rare genomic alteration, called an NTRK gene fusion, the drugmaker said on Monday.
NTRK gene fusion tumors are rare cancers affecting both children and adults and occur in varying frequencies across various tumor types.
Vitrakvi, which was exclusively designed to treat tumors that have an NTRK gene fusion, has demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including central nervous system tumors.
It is already approved in the US, Brazil and Canada.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
NTRK gene fusion tumors are rare cancers affecting both children and adults and occur in varying frequencies across various tumor types.
Vitrakvi, which was exclusively designed to treat tumors that have an NTRK gene fusion, has demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including central nervous system tumors.
It is already approved in the US, Brazil and Canada.
Copyright (c) 2019 CercleFinance.com. All rights reserved.